245 related articles for article (PubMed ID: 27180007)
1. Administration of probiotic kefir to mice with Clostridium difficile infection exacerbates disease.
Spinler JK; Brown A; Ross CL; Boonma P; Conner ME; Savidge TC
Anaerobe; 2016 Aug; 40():54-7. PubMed ID: 27180007
[TBL] [Abstract][Full Text] [Related]
2. Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites.
Wang J; Ghali S; Xu C; Mussatto CC; Ortiz C; Lee EC; Tran DH; Jacobs JP; Lagishetty V; Faull KF; Moller T; Rossetti M; Chen X; Koon HW
Gastroenterology; 2018 May; 154(6):1737-1750. PubMed ID: 29360463
[TBL] [Abstract][Full Text] [Related]
3. Defined Nutrient Diets Alter Susceptibility to Clostridium difficile Associated Disease in a Murine Model.
Moore JH; Pinheiro CC; Zaenker EI; Bolick DT; Kolling GL; van Opstal E; Noronha FJ; De Medeiros PH; Rodriguez RS; Lima AA; Guerrant RL; Warren CA
PLoS One; 2015; 10(7):e0131829. PubMed ID: 26181795
[TBL] [Abstract][Full Text] [Related]
4. Staggered and tapered antibiotic withdrawal with administration of kefir for recurrent Clostridium difficile infection.
Bakken JS
Clin Infect Dis; 2014 Sep; 59(6):858-61. PubMed ID: 24917658
[TBL] [Abstract][Full Text] [Related]
5. Probiotics for prevention of Clostridium difficile infection.
Mills JP; Rao K; Young VB
Curr Opin Gastroenterol; 2018 Jan; 34(1):3-10. PubMed ID: 29189354
[TBL] [Abstract][Full Text] [Related]
6. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.
Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL
Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481
[TBL] [Abstract][Full Text] [Related]
7. Recurrent Clostridium difficile infections: the importance of the intestinal microbiota.
Zanella Terrier MC; Simonet ML; Bichard P; Frossard JL
World J Gastroenterol; 2014 Jun; 20(23):7416-23. PubMed ID: 24966611
[TBL] [Abstract][Full Text] [Related]
8. Probiotics as adjunctive therapy for preventing Clostridium difficile infection - What are we waiting for?
Spinler JK; Ross CL; Savidge TC
Anaerobe; 2016 Oct; 41():51-57. PubMed ID: 27180657
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota.
McDonald JAK; Mullish BH; Pechlivanis A; Liu Z; Brignardello J; Kao D; Holmes E; Li JV; Clarke TB; Thursz MR; Marchesi JR
Gastroenterology; 2018 Nov; 155(5):1495-1507.e15. PubMed ID: 30025704
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets.
Kim HB; Zhang Q; Sun X; Beamer G; Wang Y; Tzipori S
Antimicrob Agents Chemother; 2014 Dec; 58(12):7560-4. PubMed ID: 25267665
[TBL] [Abstract][Full Text] [Related]
11. IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection.
Frisbee AL; Saleh MM; Young MK; Leslie JL; Simpson ME; Abhyankar MM; Cowardin CA; Ma JZ; Pramoonjago P; Turner SD; Liou AP; Buonomo EL; Petri WA
Nat Commun; 2019 Jun; 10(1):2712. PubMed ID: 31221971
[TBL] [Abstract][Full Text] [Related]
12. A human gut ecosystem protects against C. difficile disease by targeting TcdA.
Martz SL; Guzman-Rodriguez M; He SM; Noordhof C; Hurlbut DJ; Gloor GB; Carlucci C; Weese S; Allen-Vercoe E; Sun J; Claud EC; Petrof EO
J Gastroenterol; 2017 Apr; 52(4):452-465. PubMed ID: 27329502
[TBL] [Abstract][Full Text] [Related]
13. Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains.
Theriot CM; Koumpouras CC; Carlson PE; Bergin II; Aronoff DM; Young VB
Gut Microbes; 2011; 2(6):326-34. PubMed ID: 22198617
[TBL] [Abstract][Full Text] [Related]
14. Humanized microbiota mice as a model of recurrent Clostridium difficile disease.
Collins J; Auchtung JM; Schaefer L; Eaton KA; Britton RA
Microbiome; 2015 Aug; 3():35. PubMed ID: 26289776
[TBL] [Abstract][Full Text] [Related]
15. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile.
Britton RA; Young VB
Gastroenterology; 2014 May; 146(6):1547-53. PubMed ID: 24503131
[TBL] [Abstract][Full Text] [Related]
16. The microbiota and immune response during Clostridium difficile infection.
Buonomo EL; Petri WA
Anaerobe; 2016 Oct; 41():79-84. PubMed ID: 27212111
[TBL] [Abstract][Full Text] [Related]
17. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.
Nitzan O; Elias M; Chazan B; Raz R; Saliba W
World J Gastroenterol; 2013 Nov; 19(43):7577-85. PubMed ID: 24282348
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiota.
Nagao-Kitamoto H; Leslie JL; Kitamoto S; Jin C; Thomsson KA; Gillilland MG; Kuffa P; Goto Y; Jenq RR; Ishii C; Hirayama A; Seekatz AM; Martens EC; Eaton KA; Kao JY; Fukuda S; Higgins PDR; Karlsson NG; Young VB; Kamada N
Nat Med; 2020 Apr; 26(4):608-617. PubMed ID: 32066975
[TBL] [Abstract][Full Text] [Related]
19. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.
Weingarden AR; Chen C; Bobr A; Yao D; Lu Y; Nelson VM; Sadowsky MJ; Khoruts A
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G310-9. PubMed ID: 24284963
[TBL] [Abstract][Full Text] [Related]
20. Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain.
Pawlowski SW; Calabrese G; Kolling GL; Platts-Mills J; Freire R; AlcantaraWarren C; Liu B; Sartor RB; Guerrant RL
J Infect Dis; 2010 Dec; 202(11):1708-12. PubMed ID: 20977342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
